Publications by authors named "M Deimling"
Article Synopsis
- The study aimed to evaluate how effective first-line immune checkpoint inhibitor (ICI) combinations are for treating metastatic renal cell carcinoma (mRCC) patients based on age.
- After reviewing five randomized controlled trials, the results showed that ICI combinations significantly improved overall survival (OS) compared to sunitinib alone for both younger (<65 years) and older (≥65 years) patients, but the benefit was notably greater for younger patients.
- The findings suggest that ICI combinations did not enhance OS for patients aged 75 and older, indicating that age can influence treatment decisions and patient outcomes.
We aimed to review the evidence of reducing the dose or number of BCG instillations in non-muscle invasive bladder cancer (NMIBC) patients. A literature search was done according to Preferred Reporting Items for Meta-Analyses statement. Overall, 15 and 13 studies were eligible for qualitative and quantitative synthesis, respectively.
View Article and Find Full Text PDF(1) Background: Several phase II studies, including randomized controlled trials (RCTs), assessed the efficacy of adding androgen receptor signaling inhibitors (ARSIs) to androgen deprivation therapy (ADT) as a neoadjuvant treatment in patients treated with radical prostatectomy (RP) for prostate cancer (PCa). Summarizing the early results of these studies could help in designing phase III trials and patient counseling. (2) Methods: We queried three databases in January 2023 for studies that included PCa patients treated with neoadjuvant ARSI-based combination therapy before RP.
View Article and Find Full Text PDF(1) Background: Local therapy is highly promising in a multimodal approach strategy for patients with low-volume metastatic prostate cancer (mPCa). We aimed to systematically assess and summarize the safety, oncologic, and functional outcomes of cytoreductive prostatectomy (cRP) in mPCa. (2) Methods: Three databases were queried in September 2022 for publications that analyzed mPCa patients treated with cytoreductive prostatectomy without restrictions.
View Article and Find Full Text PDFContext: The ablative effect of intravesical therapy is known for decades. However, the clinical feasibility and efficacy of chemoablation for non-muscle-invasive bladder cancer (NMIBC) have not become accepted.
Objective: To assess the treatment outcomes of chemoablation for NMIBC and to compare its safety with that of the standard treatment, transurethral resection of bladder tumors (TURBT) followed by intravesical therapy.